These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 10366362)

  • 1. Economics and Cost-Effectiveness in Evaluating the Value of Cardiovascular Therapies. Proceedings of a symposium. St. Petersburg, Florida, USA. April 17-20, 1997.
    Am Heart J; 1999 May; 137(5):S35-144. PubMed ID: 10366362
    [No Abstract]   [Full Text] [Related]  

  • 2. Proceedings of a symposium: economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful health economic study for the pharmaceutical industry?
    Gagnon JP
    Am Heart J; 1999 May; 137(5):S62-6. PubMed ID: 10220599
    [No Abstract]   [Full Text] [Related]  

  • 3. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Statistical issues in cost-effectiveness analysis.
    DeLong ER; Simons T
    Am Heart J; 1999 May; 137(5):S47-50. PubMed ID: 10220596
    [No Abstract]   [Full Text] [Related]  

  • 4. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Terminology I would like to see disappear.
    Detsky AS
    Am Heart J; 1999 May; 137(5):S51-2. PubMed ID: 10220597
    [No Abstract]   [Full Text] [Related]  

  • 5. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. A survey of standards and guidelines for cost-effectiveness analysis in health care.
    Stewart A; Schmier JK; Luce BR
    Am Heart J; 1999 May; 137(5):S53-61. PubMed ID: 10220598
    [No Abstract]   [Full Text] [Related]  

  • 6. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Product labeling and pharmacoeconomic information.
    Morris LA
    Am Heart J; 1999 May; 137(5):S78-80. PubMed ID: 10220603
    [No Abstract]   [Full Text] [Related]  

  • 7. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
    Temple R
    Am Heart J; 1999 May; 137(5):S75-7. PubMed ID: 10220602
    [No Abstract]   [Full Text] [Related]  

  • 8. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of economic models in randomized clinical trials.
    Hlatky MA
    Am Heart J; 1999 May; 137(5):S41-6. PubMed ID: 10220595
    [No Abstract]   [Full Text] [Related]  

  • 9. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. What constitutes a useful economic study? The health systems perspective.
    Lee TH
    Am Heart J; 1999 May; 137(5):S67-70. PubMed ID: 10220600
    [No Abstract]   [Full Text] [Related]  

  • 10. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Consortium perspective: what constitutes a useful economic study?
    Chen C; Vlasses PH
    Am Heart J; 1999 May; 137(5):S71-4. PubMed ID: 10220601
    [No Abstract]   [Full Text] [Related]  

  • 11. The cost-effectiveness of cardiovascular medicine in Greece: brief notes.
    Vardas PE
    Hellenic J Cardiol; 2012; 53(4):333-4. PubMed ID: 22796825
    [No Abstract]   [Full Text] [Related]  

  • 12. Evaluating the costs and effectiveness of cardiovascular therapies: who cares about economic analyses?
    Califf RM
    Stat Med; 2002 Oct; 21(19):2889-97. PubMed ID: 12325105
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Evaluating the economic implications of cardiovascular therapeutics.
    Califf RM
    Am Heart J; 1999 May; 137(5):S35-7. PubMed ID: 10220593
    [No Abstract]   [Full Text] [Related]  

  • 14. Current trends in cardiovascular therapy.
    Palmaz JC
    J Cardiovasc Surg (Torino); 2009 Feb; 50(1):3-6. PubMed ID: 19179985
    [No Abstract]   [Full Text] [Related]  

  • 15. Proceedings of the 9th Annual Symposium Transcatheter Cardiovascular Therapeutics. Washington, DC, USA. September 24-28, 1997.
    Am J Cardiol; 1998 Apr; 81(7A):1E-62E. PubMed ID: 9565539
    [No Abstract]   [Full Text] [Related]  

  • 16. Cardiovascular Interventions, Coronary and Peripheral. Transcatheter Cardiovascular Therapeutics 10th annual symposium. Washington, D.C., USA. October 7-11, 1998. Proceedings.
    Indian Heart J; 1998 Oct; 50 Suppl 1():1-160. PubMed ID: 9867484
    [No Abstract]   [Full Text] [Related]  

  • 17. Common sense, dollars and cents, and drug-eluting stents.
    Vaitkus PT
    J Am Coll Cardiol; 2006 Jul; 48(2):268-9. PubMed ID: 16843173
    [No Abstract]   [Full Text] [Related]  

  • 18. [The elderly cardiovascular patient in general practice. Health care costs--drugs--economic feasibility].
    Schmidt K
    Fortschr Med; 1996 Mar; 114(7):43-4. PubMed ID: 8900969
    [No Abstract]   [Full Text] [Related]  

  • 19. Drug-coated balloons are replacing the need for nitinol stents in the superficial femoral artery.
    Kitrou P; Karnabatidis D; Katsanos K
    J Cardiovasc Surg (Torino); 2016 Aug; 57(4):569-77. PubMed ID: 27128105
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cost effectiveness of cardiovascular medicines.
    Hay J
    Curr Atheroscler Rep; 2005 Mar; 7(2):79-80. PubMed ID: 15727719
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.